Navigation Links
Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009
Date:2/17/2009

LAIYANG, China, Feb. 17 /PRNewswire-Asia-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced its financial results for the second quarter of its fiscal year 2009 ended December 31, 2008.

    Second Quarter of Fiscal Year 2009 Highlights

    -- Revenue was $32.9 million, up 24.1% from the corresponding quarter
       ended December 31, 2007
    -- Gross profit was $25.8 million, up 30.8% from the corresponding
       quarter ended December 31, 2007, and gross margin was 78.3%,
       compared to 74.3% in the corresponding quarter ended December 31,
       2007
    -- Operating income was $11.4 million, up 34.7% from the corresponding
       quarter ended December 31, 2007
    -- Net income was $5.4 million, or $0.11 per fully diluted share, up
       from $5.2 million, or $0.02 per fully diluted share, a year ago
    -- Non-GAAP adjusted net income was $7.0 million, or $0.71 per weighted
       average share, up 28.8% from non-GAAP adjusted net income of $5.4
       million, or $0.56 per fully diluted share, for the quarter ended
       December 31, 2007
    -- The board of directors approved a $2 million share buyback program
    -- An Assets Transfer Contract was signed in January to acquire
       Shandong Hongrui Pharmaceutical Factory ("Hongrui")
    -- A new website was launched: http://www.genesispharmaceuticals.com/

"We are pleased to report that Genesis Pharmaceuticals continued to show solid financial performance in the second quarter of our fiscal year 2009. Increased sales of Itopride Hydrochloride Granules and Baobaole Chewable Tablets led to strong revenue and operations income growth," said Mr. Wubo Cao, Chairman and CEO of Genesis. "And, sales o
'/>"/>

SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
2. Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area
3. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
4. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. OmegaGenesis Announces Angiogenesis Application Collaboration
7. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
8. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
9. Cardiogenesis Reports Third Quarter 2008 Results
10. ThermoGenesis Presentation at Rodman & Renshaw Conference
11. Genesis Pharmaceuticals Launches New Corporate Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... LEXINGTON, Mass. , Dec. 17, 2014   ... a biopharmaceutical company developing therapeutic products for rare disorders, ... Healthcare Conference being held in San Francisco, ... , President and Chief Executive Officer, will present on ... p.m. EST).  The presentation will be webcast live and ...
(Date:12/15/2014)... NEW YORK , Dec. 15, 2014  GlassesOff ... Yuval Bar-Gil as an independent director of ... was founder of AeroScout and served as its CEO ... Decker in 2012, a $240 million transaction. Recognized as ... under Mr. Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID ...
(Date:12/13/2014)... and Virgin Unite Canada, the non-profit foundation of the Virgin ... Canadian entrepreneurs tackling social and environmental challenges. Today, Sir ... Centre to announce the new partnership, which includes the development ... $1 million in seed capital provided by Virgin Unite Canada ... Foundation, founded by Alison Lawton . ...
(Date:12/13/2014)... The “Global Synthetic Biology Market (2013-2018)”, analyses ... and challenges. , The global synthetic biology market ... Fisher Scientific, Inc. (U.S.), DuPont (U.S.), and Royal ... approximately ~65% of the total synthetic biology market. ... Report @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html , Thermo Fisher ...
Breaking Biology Technology:AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3
... -- JERUSALEM and NEEDHAM, Massachusetts, August 18, 2010, ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in ...
... Fuels, Inc., a company focused on commercially producing low-carbon ... has produced cellulosic methanol from the initial phase of ... using non-food biomass. The first phase of ... thermo-chemical process, which uses heat, pressure, and steam to ...
... VANCOUVER, Canada, Aug. 17 Xenon Pharmaceuticals Inc. announced ... trial evaluating its novel topical XEN402 therapy for the ... developed by Xenon as a topical ointment formulation and ... 1 study in normal human volunteers.  The product was ...
Cached Biology Technology:Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 2Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 3Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 4Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 5Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 6Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 7Range Fuels Produces Cellulosic Methanol From First Commercial Cellulosic Biofuels Plant 2Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402. 2
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... replanting of mangroves on the coasts of the Philippines could ... typhoons that hit the islands annually. This is one ... and massive mangrove replanting, that J.H. Primavera from the Southeast ... Salle University, both in the Philippines, cite in a paper ...
... technology used for building batteries for countless portable electronic ... economy is already upon us. In a ... International Journal of Nuclear Hydrogen Production and Applications , ... based in Bloomfield Hills, Michigan, explains that we already ...
... treatment of Alzheimer,s disease reports improvement in language ... accompanying the research, published today in the open ... within minutes of using this new treatment. ... published in BioMed Central,s Journal of Neuroinflammation, ...
Cached Biology News:Mangroves key to saving lives 2Closing the hydrogen economic loop 2
... The Rotofor purification system, 100-120 V, is ... liquid-phase isoelectric focusing (IEF). The system includes ... (60 ml) focusing chambers, chassis, harvesting apparatus, ... ampholytes (pH 3-10), 60 ml syringe, colored ...
... BCIP/NBT Chromogen system consists of ... in a single component,solution. The ... the presence of alkaline phosphatase ... minimal background noise. ,The System ...
Mouse monoclonal antibody raised against a partial recombinant VEGFB. NCBI Entrez Gene ID = VEGFB...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
Biology Products: